Effect of vascular endothelial growth factor siRNA and wild‑type p53 co‑expressing plasmid in MDA‑MB‑231 cells

作者: HUA GUO , YANG LI , JUNLIAN GU , YUE WANG , LIANQIN LIU

DOI: 10.3892/MMR.2015.4571

关键词:

摘要: Breast cancer urgently requires improved therapeutic strategies. In the current study, a Pvp53 plasmid that co‑expressed p53 and short‑interfering RNA against vascular endothelial growth factor (si‑VEGF) was developed to replace single transfections. Whether exhibited anti‑tumor effects in breast MDA‑MB‑231 cells investigated present study. significantly reduced Bcl‑2/Bax ratio increased expression of cleaved caspase‑3 8. Compared with si‑VEGF transfections, co‑expression proportion apoptotic inhibited cell motility proliferation. These results indicated has greater inhibitory on than plasmids.

参考文章(49)
Dietmar W. Siemann, Michael R. Horsman, Modulation of the tumor vasculature and oxygenation to improve therapy Pharmacology & Therapeutics. ,vol. 153, pp. 107- 124 ,(2015) , 10.1016/J.PHARMTHERA.2015.06.006
Soumitro Pal, Debabrata Mukhopadhyay, Kaustubh Datta, Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Expression in Mammary Carcinoma Cancer Research. ,vol. 61, pp. 6952- 6957 ,(2001)
Faton Agani, David G. Kirsch, Gregg L. Semenza, Scott L. Friedman, Michael B. Kastan, p53 Does Not Repress Hypoxia-induced Transcription of the Vascular Endothelial Growth Factor Gene Cancer Research. ,vol. 57, pp. 4474- 4477 ,(1997)
Yong Weon Yi, Hyo Jin Kang, Hee Jeong Kim, Yali Kong, Milton L. Brown, Insoo Bae, Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells Oncotarget. ,vol. 4, pp. 984- 994 ,(2013) , 10.18632/ONCOTARGET.1070
Tian-Bao WANG, Jin WANG, Xiu-Qing WEI, Bo WEI, Wen-Guang DONG, Serum vascular endothelial growth factor-C combined with multi-detector CT in the preoperative diagnosis of lymph node metastasis of gastric cancer Asia-pacific Journal of Clinical Oncology. ,vol. 8, pp. 180- 186 ,(2012) , 10.1111/J.1743-7563.2011.01490.X
Evrim Gurpinar, Karen H. Vousden, Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation Trends in Cell Biology. ,vol. 25, pp. 486- 495 ,(2015) , 10.1016/J.TCB.2015.04.001
Leonidas Tsiokas, Vikas P. Sukhatme, Debabrata Mukhopadhyay, Wild-Type p53 and v-Src Exert Opposing Influences on Human Vascular Endothelial Growth Factor Gene Expression Cancer Research. ,vol. 55, pp. 6161- 6165 ,(1995)
Ronnie Tung-Ping Poon, Sheung-Tat Fan, John Wong, Clinical Implications of Circulating Angiogenic Factors in Cancer Patients Journal of Clinical Oncology. ,vol. 19, pp. 1207- 1225 ,(2001) , 10.1200/JCO.2001.19.4.1207
Ran Brosh, Varda Rotter, When mutants gain new powers: news from the mutant p53 field Nature Reviews Cancer. ,vol. 9, pp. 701- 713 ,(2009) , 10.1038/NRC2693